{"precision": 0.6666666666666666, "recall": 0.8, "macro_F1": 0.7272727272727273, "micro_F1": 0.7083333333333334, "accuracy": 0.5, "correct_cases": {"2566": {"text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .", "true": [["lethal anuria", "ifosfamide"]], "pred": [["lethal anuria", "ifosfamide"]], "response": " [['lethal anuria', 'ifosfamide']]\nExplanation: High dose ifosfamide chemotherapy caused lethal anuria in a breast cancer patient with impaired renal function."}, "2399": {"text": "Gemcitabine - induced pulmonary toxicity is usually a dramatic condition .", "true": [["pulmonary toxicity", "gemcitabine"]], "pred": [["pulmonary toxicity", "gemcitabine"]], "response": " [['pulmonary toxicity', 'gemcitabine']]\nExplanation: Gemcitabine-induced pulmonary toxicity is a known adverse effect of the drug."}, "1190": {"text": "In this article , we describe another case of subcutaneous changes following repeated glatiramer acetate injection , presented as localized panniculitis in the area around the injection sites , in a 46-year - old female patient who was treated with glatiramer acetate for 18 months .", "true": [["localized panniculitis", "glatiramer acetate"], ["localized panniculitis", "glatiramer acetate"], ["subcutaneous changes", "glatiramer acetate"]], "pred": [["subcutaneous changes", "glatiramer acetate"], ["localized panniculitis", "glatiramer acetate"]], "response": " [['subcutaneous changes', 'glatiramer acetate'], ['localized panniculitis', 'glatiramer acetate']] \nExplanation: The patient experienced subcutaneous changes and localized panniculitis after receiving repeated injections of glatiramer acetate for 18 months."}}, "fail_cases": {"83": {"text": "We conclude that ( a ) cyclophosphamide is a human teratogen , ( b ) a distinct phenotype exists , and ( c ) the safety of CP in pregnancy is in serious question .", "true": [["human teratogen", "cyclophosphamide"]], "pred": [["human teratogen", "cyclophosphamide"], ["distinct phenotype", "cyclophosphamide"], ["safety of cp in pregnancy", "cyclophosphamide"]], "response": " [['human teratogen', 'cyclophosphamide'], ['distinct phenotype', 'cyclophosphamide'], ['safety of CP in pregnancy', 'cyclophosphamide']]\nExplanation: Cyclophosphamide is considered a human teratogen and has a distinct phenotype. The safety of CP in pregnancy is also questioned."}, "475": {"text": "A 34-year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .", "true": [["constellation of dermatitis", "sulphasalazine"], ["fever", "sulphasalazine"], ["hepatitis", "sulphasalazine"], ["lymphadenopathy", "sulphasalazine"]], "pred": [["dermatitis", "sulphasalazine"], ["fever", "sulphasalazine"], ["lymphadenopathy", "sulphasalazine"], ["hepatitis", "sulphasalazine"]], "response": " [['dermatitis', 'sulphasalazine'], ['fever', 'sulphasalazine'], ['lymphadenopathy', 'sulphasalazine'], ['hepatitis', 'sulphasalazine']]\nExplanation: The patient experienced multiple adverse effects after taking oral sulphasalazine for sero-negative rheumatoid arthritis. These included dermatitis, fever, lymphadenopathy, and hepatitis."}, "2979": {"text": "These findings support previous studies that showed that the use of aspirin during the antecedent illness may be a risk factor for the development of RS .", "true": [["rs", "aspirin"]], "pred": [["risk factor", "aspirin"]], "response": " [['risk factor', 'aspirin']]\nExplanation: The use of aspirin during antecedent illness may increase the risk of developing RS."}}, "missing_cases": {"475": [["constellation of dermatitis", "sulphasalazine"]], "2979": [["rs", "aspirin"]]}, "false_cases": {"83": [["distinct phenotype", "cyclophosphamide"], ["safety of cp in pregnancy", "cyclophosphamide"]], "475": [["dermatitis", "sulphasalazine"]], "2979": [["risk factor", "aspirin"]]}}